Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study-Reference-Cited by-同舟云学术

Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study

Published:2018-09 Issue:9 Volume:19 Page:1239-1246
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Lan Chun-Yan,Wang Yin,Xiong Ying,Li Jun-Dong,Shen Jing-Xian,Li Yan-Fang,Zheng Min,Zhang Yan-Na,Feng Yan-Ling,Liu Qing,Huang Hui-Qiang,Huang Xin

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Cancer statistics in China, 2015;Chen;CA Cancer J Clin,2014

3. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J Clin Oncol,2003

4. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer;Mutch;J Clin Oncol,2007

5. Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer;Markman;Cancer Manag Res,2011

Cited by 137 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study;Molecular Cancer;2024-08-09

2. SEfficacy and safety of apatinib in the treatment of patients with platinum‑resistant ovarian cancer: A systematic review and network meta‑analysis;Experimental and Therapeutic Medicine;2024-07-26

3. Apatinib combined with temozolomide in diffuse midline glioma: a novel and effective therapy;BMC Cancer;2024-06-21

4. TOP2A modulates signaling via the AKT/mTOR pathway to promote ovarian cancer cell proliferation;Cancer Biology & Therapy;2024-03-06

5. Efficacy and safety of VEGF/VEGFR inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials;BMC Women's Health;2024-01-13